News
Delivering a New “Post-COVID” Generation of RNA Therapeutics
The COVID-19 pandemic has turned RNA into a household word, but what new innovations and changes will we see in the RNA therapeutics space going forward and how many will actually reach the clinic?
Exacis Biotherapeutics Grants Eterna Therapeutics an Option to License Up To Four Allogeneic IPSC-Derived NK and T Cell Therapies
Agreement grants Eterna rights to license up to four next-generation iPS cell derived NK and T cell cancer therapies.
Exacis Biotherapeutics CEO to Serve on Expert Panel at RNA Cell Therapies Summit
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will discuss strategies for funding RNA-based cell therapies as a panel member at the RNA Cell Therapies Summit.
iPSC-Derived Cell Therapies Summit to Feature Discussion on Trailblazing Therapies for Immuno-Oncology-Panelists Include Exacis Biotherapeutics CEO
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will participate in an industry leader fireside chat focused on “Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies and Determining Future Outlook and Developments” at the 2nd iPSC-Derived Cell Therapies Summit.
Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit to Include Presentation by Exacis Biotherapeutics CEO
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will present “Strategies to Develop Safe Cell Therapies Without Compromising Efficacy” at the 3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit.
Exacis Biotherapeutics CEO to Serve on Panel at Longwood Healthcare Leaders Fall Webconference
Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will join an expert panel of biotechnology leaders to discuss “Placing Patients at the Center” during the Longwood Healthcare Leaders Fall webconference.